Latest News
Preqin’s most recent survey finds that institutional investors view mezzanine funds as one of the most promising areas of the private debt market, leading to increased fundraising for the fund type in recent quarters.
Almost half see mezzanine funds as offering the best risk/return profile, and four out of ten think they offer the best opportunities at present. As a result, investors are seeking out mezzanine investments: the greatest proportion of active investor mandates tracked by Preqin are for mezzanine vehicles. Increased investor interest may partly explain strong fundraising in recent years – 2016 was a record year for mezzanine
Private equity firm Angeles Equity Partners (AEP) has added three to its team. Maxwell Schechter joins the firm as Vice President of Business Development, focusing on deal origination and marketing. James Lee and Shan Siddiqui join AEP as Associates concentrating on the evaluation, due diligence and execution of new investment opportunities.
Angeles Equity Partners I, and its parallel funds (collectively, “AEP I”) have USD360 million in capital commitments from a diverse group of institutional investors, including public and private pension plans, endowments, foundations, a sovereign wealth fund, and alternative asset managers in North America and Europe. AEP I focuses on
Private equity firm Calculus Capital, a leading EIS and VCT investor, has completed its third deal in two weeks, investing GBP2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells.
Axol supplies high quality human cells – especially live human neurons – created by stem cell technology, to many of the world’s biggest and best-known pharma companies and research institutions. These cells are used for medical research, disease modelling and drug development. Axol’s impressive client list includes top global pharmaceutical and biotech companies as well as leading academic institutes, such as
TowerBrook Capital Partners-backed Gravity Media Group (GMG), which acquires businesses serving the live broadcast sector, has appointed Paul Greensmith as its new Chief Financial Officer to oversee the company’s growth strategy.
Following recent acquisitions and investment, GMG’s current companies include Gearhouse Broadcast, Hyperactive Broadcast and Input Media – companies that supply technical equipment, facilities and services to capture live and near live content to broadcasters, production companies and rights holders around the world.
Paul Greensmith has over 15 years’ experience working as a Chief Financial Officer with private equity owners across a range of sectors. Roles included positions at
An affiliate of HIG Capital (HIG), a global private equity investment firm with USD22 billion of equity capital under management, has acquired NCI, a diversified IT and professional services company that provides software development, information assurance, IT system engineering and modernisation and other enterprise IT solutions primarily to the US Department of Defence, Intelligence Community, and federal health and civilian agencies.
Paul Dillahay, CEO of NCI, says: “We are excited about our partnership with HIG and what it means for our customers and employees. This partnership with HIG Capital will offer NCI an opportunity to accelerate our growth strategy; enhance
Global law firm Jones Day has appointed Charles Chau as a partner in the firm’s M&A Practice in Hong Kong.
An adviser for nearly 20 years to clients in Hong Kong, mainland China, and the Asia-Pacific region, Chau has extensive experience in public and private company acquisitions, joint ventures, financings, and pre-IPO investment transactions. His experience encompasses a wide range of industry sectors, including banking and financial services, health care, biotech, retail, real estate, and manufacturing.
“Charles brings tremendous experience to our transaction capabilities in the region,” says Joelle Lau, Partner-in-Charge of Jones Day’s Hong Kong Office. “Given the
Maven Capital Partners (Maven) has appointed Craig Hopwood as an Investment Director, based in the Manchester office.
Hopwood joins from HSBC where he was responsible for looking after a portfolio of larger private equity-backed businesses across the region including Fircroft, Tangerine and Innovia. Prior to this, he worked in the private equity teams at Northstar Equity Investors and Spirit Capital Partners LLP, having previously been part of PriceWaterhouseCoopers’ Corporate Finance Private Equity advisory team.
At Maven, Hopwood will be responsible for sourcing and leading new growth capital and private equity investments across the North of England. In addition to
NGX Bio has closed a USD3 million funding round led by 180 Degree Capital Corp with participation from Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors.
NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally. Demand for sequencing services is growing exponentially. NGX Bio’s platform matches the sequencing needs of customers with providers who have available sequencing capacity. Customers are able to purchase a wide range of
SnapApp, provider of an SaaS platform used by B2B marketers to create, publish, and measure interactive content, has closed USD10.2 million in additional funding from its principal investor, Providence Strategic Growth, the growth equity affiliate of Providence Equity Partners.
The Series B round follows a period of sustained and rapid growth for SnapApp over the past two years as interactive marketing has increasingly become a must-have for modern marketers.
Founded in 2011, SnapApp empowers marketers to create personalised interactive experiences that accelerates leads, activates buyers through the funnel, and unleash growth. Its interactive content creation platform easily lets marketers
VentureMed Group (VMG), a medical device company developing and commercialising next-generation endovascular products to treat patients suffering from peripheral artery disease (PAD), has raised USD15 million in new equity financing.
The Series B Round was led by new investor Endeavour Vision, a technology and life science investor based in Geneva, Switzerland, and also included new investor RiverVest Venture Partners, a St Louis, MO, based venture capital firm dedicated to life science and healthcare investing.
“We are very pleased to have Endeavour Vision’s and RiverVest Venture Partners’ support to help build our team and expand our product line, enabling us
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
